The bark of the Amur cork tree, stripped and dried, has been boiled into remedies for arthritic joints in Chinese medicine for roughly five centuries. Practitioners had little way of knowing what, precisely, was doing the work. Now a team of researchers from Heilongjiang University of Chinese Medicine and collaborators in Guangdong think they’ve pinned it down: a molecule called obakulactone, and a mechanism nobody had thought to look for in the greasy biochemistry of fat metabolism. The finding, published in the journal Engineering, doesn’t just offer a candidate drug. It reframes what rheumatoid arthritis might fundamentally be.
About 1% of people worldwide carry an RA diagnosis, a figure that sounds modest until you think about what the disease does: the synovial membrane lining the joints thickens and inflames, cartilage erodes, bone deforms. Current treatments, including methotrexate, NSAIDs, and glucocorticoids, manage symptoms for many patients but carry serious costs. Prolonged use can suppress bone marrow, damage the liver, and increase cardiovascular risk. The search for something better has pushed researchers toward natural compounds, partly from frustration, partly because traditional medicine sometimes turns out to have been quietly right all along.
The Fatty Acid Connection
What makes the new work unusual is where the researchers looked. Most RA research concentrates on immune signalling cascades, the cytokines and T-cell responses that drive joint inflammation. The Heilongjiang team came at it from a different angle, using metabolomics to scan the blood of arthritic rats for chemical fingerprints of disease. They found 34 candidate biomarkers, and a striking proportion of them belonged to the same family: unsaturated fatty acids. Arachidonic acid, linoleic acid, 5-HETE. These compounds aren’t incidental, it turns out. They’re proinflammatory by nature, and in joints with active RA, their production appears to be running out of control.
The enzyme responsible, or at least a pivotal one, is ACOT1 (acyl coenzyme A thioesterase 1). Its job is to cleave fatty acid chains from their coenzyme A carriers, releasing free fatty acids, including arachidonic acid, into cells. In healthy tissue this is routine housekeeping. In inflamed RA joints, ACOT1 appears to be overexpressed, flooding the joint environment with substrates that the body converts into prostaglandins, leukotrienes, and other inflammatory mediators. Those mediators, in turn, activate two signalling pathways, PI3K-AKT and JAK-STAT, that are well-established drivers of the abnormal fibroblast growth central to RA pathology.
Synovial fibroblasts are the cells that make RA structurally destructive. Normally they maintain joint architecture. In RA they turn invasive, secreting enzymes that degrade cartilage and bone matrix, proliferating in ways that recall tumour cells. Targeting them is the goal of several modern RA therapies; the JAK inhibitors tofacitinib and baricitinib work in part by interrupting the same JAK-STAT pathway. Obakulactone, the researchers found, hits the same destination by a different route.
How the Molecule Does It
Confirming that obakulactone directly binds ACOT1 required several converging lines of evidence. In cellular thermal shift assays, the compound stabilised ACOT1 against heat denaturation (a hallmark of direct protein binding). Microscale thermophoresis put the binding affinity at a dissociation constant of around 6.2 micromolar; surface plasmon resonance, using a different detection method entirely, returned a number that was essentially the same. These aren’t the kind of results you can explain away as coincidence. Molecular docking modelling suggested obakulactone nestles against a specific asparagine residue in the ACOT1 active site, held in place by a hydrogen bond with a binding energy of roughly minus 15 kilocalories per mole, well beyond the threshold considered good affinity.
What the molecule does after binding is perhaps the more interesting part. Rather than simply blocking ACOT1 activity, obakulactone appears to mark the protein for destruction by the cell’s own waste-disposal machinery. The ubiquitin-proteasome system, which the cell uses to tag and degrade unwanted proteins, became significantly more active against ACOT1 in treated cells. When the researchers added MG132, a drug that blocks the proteasome, ACOT1 levels recovered, confirming that obakulactone was driving its target toward degradation rather than just inhibiting it in situ. This distinction matters: degrading a protein removes it from the cell entirely, whereas merely blocking it can sometimes be reversed by displacement or competition.
The rescue experiment was probably the most persuasive piece of evidence in the paper. If obakulactone works by reducing arachidonic acid production via ACOT1 suppression, then flooding cells with exogenous arachidonic acid should undo its effects. That’s precisely what happened. The compound’s ability to slow fibroblast proliferation and drive apoptosis was substantially reversed when arachidonic acid was added back. Then the researchers tried the experiment from the other direction: pre-treating cells with pharmacological inhibitors of PI3K and JAK before adding obakulactone. There was no additive benefit, suggesting the two approaches were targeting the same bottleneck. The downstream machinery was already shut off; obakulactone had nothing further to do.
An Immune Shift, Not Just an Inflammatory One
The effects extended beyond fibroblasts. In arthritic rats, obakulactone shifted macrophage populations from the M1 (proinflammatory) phenotype toward M2 (anti-inflammatory), a transition associated with tissue resolution rather than tissue destruction. It also reduced the proportion of CD4+ T cells differentiating into Th17 cells, a subset implicated in driving synovial inflammation. Serum levels of IL-6, TNF-alpha, and other inflammatory markers dropped in a dose-dependent manner, with the highest obakulactone dose producing results close to the control group and broadly comparable to methotrexate, the standard-of-care comparator used in the study.
There are caveats worth noting. The CFA rat model used here replicates some features of human RA well (joint swelling, cartilage erosion, fibroblast activation) but is not a perfect mirror of the complex adaptive immune involvement seen in human disease. The researchers acknowledge this and say they are now gathering clinical samples from RA patients for correlation studies. The jump from rodent pharmacology to human therapy is not automatic, and obakulactone has not been tested in people.
Still, the conceptual contribution may matter regardless of what happens to this particular molecule in clinical development. The idea that unsaturated fatty acid metabolism is a mechanistically meaningful lever in RA, not merely a correlate of inflammation, opens a different set of targets. ACOT1, largely overlooked in autoimmune research until now, joins a growing list of metabolic enzymes being reconsidered as entry points for immune disease. It’s possible, though not yet demonstrated, that dietary interventions affecting arachidonic acid precursors could modulate the same pathway. The pharmacology is probably more controllable than a meal plan, but the underlying biology suggests the connection is real. Five hundred years of bark-based medicine may have been pointing, in its oblique way, at something worth knowing.
https://doi.org/10.1016/j.eng.2025.10.029
Frequently Asked Questions
What is obakulactone and where does it come from?
Obakulactone is a naturally occurring compound classified as a tetracyclic triterpenoid, extracted from Phellodendri cortex, the dried bark of the Amur cork tree. The bark has been used in traditional Chinese medicine for joint conditions for roughly five centuries, though the specific compound and its mechanism were not identified until recently.
How is this different from existing rheumatoid arthritis treatments?
Current treatments like methotrexate and JAK inhibitors work primarily by suppressing immune signalling or blocking specific inflammatory cytokines. Obakulactone acts upstream by targeting ACOT1, an enzyme involved in fatty acid metabolism, promoting its destruction via the cell’s own protein-disposal machinery. This metabolic approach is mechanistically distinct from existing therapies, though it ultimately converges on some of the same inflammatory pathways.
Why does fatty acid metabolism matter in rheumatoid arthritis?
Enzymes like ACOT1 release arachidonic acid and related fatty acids from storage, and these molecules are direct precursors to prostaglandins and leukotrienes, potent chemical mediators of inflammation. In RA joints, ACOT1 appears overactive, generating an excess of these proinflammatory lipids. Reducing ACOT1 activity cuts off this supply chain and dampens the downstream signalling that drives synovial fibroblast proliferation and joint destruction.
Is obakulactone ready to use as a treatment?
Not yet. The research was conducted in rats, and while the results are promising, animal models don’t always predict human outcomes reliably. The researchers have not yet reported clinical trials in human patients, and significantly more safety and efficacy testing would be required before obakulactone could be considered for medical use. The team is reportedly collecting clinical samples from RA patients as a next step.
Could diet affect the same pathway that obakulactone targets?
Possibly, in principle. Arachidonic acid, the proinflammatory fatty acid amplified by ACOT1 overactivity, is obtained partly from dietary sources like red meat and eggs. Omega-3 fatty acids found in fish compete with arachidonic acid in inflammatory pathways, which is why dietary interventions are sometimes discussed in RA management. The new research doesn’t directly test dietary effects, but it does clarify the mechanistic importance of arachidonic acid metabolism in joint inflammation, which lends some biochemical plausibility to the diet-inflammation link.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.